Dr. Reddy's Laboratories (NYSE:RDY - Get Free Report) was downgraded by StockNews.com from a "strong-buy" rating to a "buy" rating in a report released on Tuesday.
A number of other research analysts also recently weighed in on the company. Jefferies Financial Group downgraded Dr. Reddy's Laboratories from a "buy" rating to an "underperform" rating in a report on Thursday, January 11th. Barclays lifted their price target on Dr. Reddy's Laboratories from $75.00 to $80.00 and gave the company an "overweight" rating in a report on Monday, January 29th. One investment analyst has rated the stock with a sell rating, two have issued a hold rating and two have issued a buy rating to the company. Based on data from MarketBeat, the stock presently has a consensus rating of "Hold" and a consensus target price of $80.00.
Get Our Latest Report on RDY
Dr. Reddy's Laboratories Price Performance
Shares of NYSE RDY traded down $0.95 during mid-day trading on Tuesday, reaching $73.47. The company had a trading volume of 181,960 shares, compared to its average volume of 195,432. The company has a current ratio of 2.55, a quick ratio of 1.90 and a debt-to-equity ratio of 0.02. The stock has a market cap of $12.26 billion, a PE ratio of 19.39, a P/E/G ratio of 1.86 and a beta of 0.58. The company has a 50-day moving average price of $74.15 and a two-hundred day moving average price of $70.54. Dr. Reddy's Laboratories has a 1-year low of $53.12 and a 1-year high of $77.72.
Dr. Reddy's Laboratories (NYSE:RDY - Get Free Report) last issued its earnings results on Wednesday, January 31st. The company reported $0.99 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of $0.88 by $0.11. The business had revenue of $867.00 million for the quarter, compared to analysts' expectations of $827.81 million. Dr. Reddy's Laboratories had a return on equity of 20.97% and a net margin of 19.26%. On average, equities analysts anticipate that Dr. Reddy's Laboratories will post 3.96 earnings per share for the current year.
Institutional Inflows and Outflows
A number of institutional investors and hedge funds have recently modified their holdings of RDY. Lindbrook Capital LLC boosted its position in Dr. Reddy's Laboratories by 10.1% during the first quarter. Lindbrook Capital LLC now owns 3,873 shares of the company's stock valued at $284,000 after purchasing an additional 354 shares during the last quarter. First Trust Direct Indexing L.P. boosted its position in Dr. Reddy's Laboratories by 2.4% during the first quarter. First Trust Direct Indexing L.P. now owns 10,634 shares of the company's stock valued at $780,000 after purchasing an additional 251 shares during the last quarter. Artemis Investment Management LLP acquired a new stake in Dr. Reddy's Laboratories during the first quarter valued at $594,000. Janiczek Wealth Management LLC boosted its position in Dr. Reddy's Laboratories by 39.2% during the first quarter. Janiczek Wealth Management LLC now owns 6,177 shares of the company's stock valued at $453,000 after purchasing an additional 1,740 shares during the last quarter. Finally, DGS Capital Management LLC boosted its position in Dr. Reddy's Laboratories by 15.2% during the first quarter. DGS Capital Management LLC now owns 9,922 shares of the company's stock valued at $728,000 after purchasing an additional 1,306 shares during the last quarter. Hedge funds and other institutional investors own 14.02% of the company's stock.
About Dr. Reddy's Laboratories
(
Get Free Report)
Dr. Reddy's Laboratories Limited, together with its subsidiaries, operates as an integrated pharmaceutical company worldwide. It operates through Global Generics, Pharmaceutical Services and Active Ingredients (PSAI), and Others segments. The company's Global Generics segment manufactures and markets prescription and over-the-counter finished pharmaceutical products that are marketed under a brand name or as a generic finished dosages with therapeutic equivalence to branded formulations.
Featured Stories
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.
Before you consider Dr. Reddy's Laboratories, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Dr. Reddy's Laboratories wasn't on the list.
While Dr. Reddy's Laboratories currently has a "Hold" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Looking to avoid the hassle of mudslinging, volatility, and uncertainty? You'd need to be out of the market, which isn’t viable. So where should investors put their money? Find out with this report.
Get This Free Report
